A Phase I Study of MLN6907 in Patients With Metastatic Colorectal
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
This study is a first-in-human (FIH), single-dose, open-label, phase 1 study designed to
assess the safety, pharmacokinetics (PK), distribution, and radiation dosimetry of
[68Ga]MLN6907 after a single intravenous (IV) administration. Patients with Metastatic
Colorectal Carcinoma who are scheduled for resection of liver metastases as part of their
treatment plan will be eligible for enrollment.